213 related articles for article (PubMed ID: 33584650)
1. Reduced CD5 on CD8
Alotaibi F; Vincent M; Min WP; Koropatnick J
Front Immunol; 2020; 11():584937. PubMed ID: 33584650
[TBL] [Abstract][Full Text] [Related]
2. Helper-independent, L-selectinlow CD8+ T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression.
Peng L; Kjaergaard J; Plautz GE; Weng DE; Shu S; Cohen PA
J Immunol; 2000 Nov; 165(10):5738-49. PubMed ID: 11067932
[TBL] [Abstract][Full Text] [Related]
3. Functional Heterogeneity of CD4
Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
Front Immunol; 2018; 9():2654. PubMed ID: 30505306
[TBL] [Abstract][Full Text] [Related]
4. 4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8
Kim HD; Park S; Jeong S; Lee YJ; Lee H; Kim CG; Kim KH; Hong SM; Lee JY; Kim S; Kim HK; Min BS; Chang JH; Ju YS; Shin EC; Song GW; Hwang S; Park SH
Hepatology; 2020 Mar; 71(3):955-971. PubMed ID: 31353502
[TBL] [Abstract][Full Text] [Related]
5. CD5 blockade enhances ex vivo CD8
Alotaibi F; Rytelewski M; Figueredo R; Zareardalan R; Zhang M; Ferguson PJ; Maleki Vareki S; Najajreh Y; El-Hajjar M; Zheng X; Min WP; Koropatnick J
Eur J Immunol; 2020 May; 50(5):695-704. PubMed ID: 31943150
[TBL] [Abstract][Full Text] [Related]
6. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors.
Kilinc MO; Aulakh KS; Nair RE; Jones SA; Alard P; Kosiewicz MM; Egilmez NK
J Immunol; 2006 Nov; 177(10):6962-73. PubMed ID: 17082611
[TBL] [Abstract][Full Text] [Related]
7. CD5 costimulation up-regulates the signaling to extracellular signal-regulated kinase activation in CD4+CD8+ thymocytes and supports their differentiation to the CD4 lineage.
Zhou XY; Yashiro-Ohtani Y; Toyo-Oka K; Park CS; Tai XG; Hamaoka T; Fujiwara H
J Immunol; 2000 Feb; 164(3):1260-8. PubMed ID: 10640739
[TBL] [Abstract][Full Text] [Related]
8. Human CD5 protects circulating tumor antigen-specific CTL from tumor-mediated activation-induced cell death.
Friedlein G; El Hage F; Vergnon I; Richon C; Saulnier P; Lécluse Y; Caignard A; Boumsell L; Bismuth G; Chouaib S; Mami-Chouaib F
J Immunol; 2007 Jun; 178(11):6821-7. PubMed ID: 17513730
[TBL] [Abstract][Full Text] [Related]
9. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression.
Gao X; Zhu Y; Li G; Huang H; Zhang G; Wang F; Sun J; Yang Q; Zhang X; Lu B
PLoS One; 2012; 7(2):e30676. PubMed ID: 22363469
[TBL] [Abstract][Full Text] [Related]
10. CD8-mediated type 1 antitumor responses selectively modulate endogenous differentiated and nondifferentiated T cell localization, activation, and function in progressive breast cancer.
Dobrzanski MJ; Reome JB; Hylind JC; Rewers-Felkins KA
J Immunol; 2006 Dec; 177(11):8191-201. PubMed ID: 17114496
[TBL] [Abstract][Full Text] [Related]
11. Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors.
Søndergaard H; Frederiksen KS; Thygesen P; Galsgaard ED; Skak K; Kristjansen PE; Odum N; Kragh M
Cancer Immunol Immunother; 2007 Sep; 56(9):1417-28. PubMed ID: 17285290
[TBL] [Abstract][Full Text] [Related]
12. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.
Zhang X; Niedermann G
Int J Radiat Oncol Biol Phys; 2018 May; 101(1):63-73. PubMed ID: 29534901
[TBL] [Abstract][Full Text] [Related]
13. Rescue of tumor-infiltrating lymphocytes from activation-induced cell death enhances the antitumor CTL response in CD5-deficient mice.
Tabbekh M; Franciszkiewicz K; Haouas H; Lécluse Y; Benihoud K; Raman C; Mami-Chouaib F
J Immunol; 2011 Jul; 187(1):102-9. PubMed ID: 21622855
[TBL] [Abstract][Full Text] [Related]
14. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer.
Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ
J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077
[TBL] [Abstract][Full Text] [Related]
15. CD8+ alpha beta+ T cells that lack surface CD5 antigen expression are a major lymphotactin (XCL1) source in peripheral blood lymphocytes.
Stievano L; Tosello V; Marcato N; Rosato A; Sebelin A; Chieco-Bianchi L; Amadori A
J Immunol; 2003 Nov; 171(9):4528-38. PubMed ID: 14568926
[TBL] [Abstract][Full Text] [Related]
16. IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer.
Rodolfo M; Zilocchi C; Accornero P; Cappetti B; Arioli I; Colombo MP
J Immunol; 1999 Aug; 163(4):1923-8. PubMed ID: 10438927
[TBL] [Abstract][Full Text] [Related]
17. CD4+ and CD8+ T cells have opposing roles in breast cancer progression and outcome.
Huang Y; Ma C; Zhang Q; Ye J; Wang F; Zhang Y; Hunborg P; Varvares MA; Hoft DF; Hsueh EC; Peng G
Oncotarget; 2015 Jul; 6(19):17462-78. PubMed ID: 25968569
[TBL] [Abstract][Full Text] [Related]
18. TCR repertoire intratumor heterogeneity of CD4
Zhang C; Ding H; Huang H; Palashati H; Miao Y; Xiong H; Lu Z
Int J Cancer; 2019 Feb; 144(4):818-827. PubMed ID: 30151844
[TBL] [Abstract][Full Text] [Related]
19. Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunization.
Xiao H; Peng Y; Hong Y; Huang L; Guo ZS; Bartlett DL; Fu N; Munn DH; Mellor A; He Y
J Immunol; 2013 Jun; 190(11):5866-73. PubMed ID: 23610140
[TBL] [Abstract][Full Text] [Related]
20. The Characteristics of Naive-like T Cells in Tumor-infiltrating Lymphocytes From Human Lung Cancer.
Sheng SY; Gu Y; Lu CG; Tang YY; Zou JY; Zhang YQ; Wang RF; Hong H
J Immunother; 2017 Jan; 40(1):1-10. PubMed ID: 27828929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
